Immunomedics Inc. (IMMU) Stock Quote

Stock Web

Detailed Quote for Immunomedics Inc. (IMMU)

close 52 Week Information

52 Week High

September 09,2009

Close: 6.72

52 Week Low

August 25,2010

Close: 2.81

Today

5d

1m

3m

1y

more

Last Price
2.9699

Change $
0.0399

Change %
1.36%

Tick

Bid
2.96

Bid Size
1600

Ask
2.97

Ask Size
2000

Open
2.94

High
2.97

Low
2.90

Prev Close
2.93

Last Trade
10:31

Volume
47.26 k

52 Wk Hi
6.72

52 Wk Low
2.81

Market Cap
223.64 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
75,302,660

EPS (TTM)
0.49

PE Ratio
6.00

close Exchange Information Listed On NASDAQ (NSD) Exchange
NSD

News and Media for Immunomedics Inc. (IMMU)

Sector News | Topic News

News for IMMU

Thu, Aug 26, 2010

4:00 PM

Immunomedics Announces Fiscal 2010 Results - Globe Newswire

Wed, Aug 18, 2010

10:30 AM

Immunomedics and GE Healthcare in Research Collaboration - Globe Newswire

Tue, Aug 10, 2010

8:30 AM

Immunomedics Awarded Additional U.S. Patent for Internalizing anti-CD74 Antibodies and Methods of Use - Globe Newswire

Fri, Jun 25, 2010

7:30 AM

Epratuzumab Data From Phase IIB EMBLEM(TM) Study Presented at 9th International Congress on Systemic Lupus Erythematosis - Globe Newswire

Mon, Jun 21, 2010

7:05 AM

Results From Randomized Study of Epratuzumab in Patients With Systemic Lupus Erythematosus Presented at European Rheumatology Congress - Globe Newswire

Wed, Jun 16, 2010

9:30 AM

New Data Presented from EMBLEM¿ Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus - PR Newswire

7:06 AM

New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus - Globe Newswire

2:32 AM

New data from EMBLEM(TM) study shows pipeline drug epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus - Thomson Reuters ONE

Tue, Jun 15, 2010

11:30 AM

Immunomedics Doses First Patient in Phase I/II Study of Milatuzumab-Doxorubicin Conjugate for Multiple Myeloma Therapy - Globe Newswire

Wed, Jun 09, 2010

4:47 PM

Immunomedics Announces Preclinical Results of Pretargeted Imaging and Therapy of Cancer - Globe Newswire

10:15 AM

Immunomedics Presents New Antibody for Pretargeting Epithelial Cancers at Medical Conference - Globe Newswire

Tue, Jun 08, 2010

9:01 AM

Immunomedics Reports First Clinical Experience With New Generation of Bispecific Antibody - Globe Newswire

Mon, Jun 07, 2010

8:33 AM

Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer - Globe Newswire

Fri, Jun 04, 2010

8:33 AM

Immunomedics to Present at Upcoming Investor Conferences - Globe Newswire

Tue, Jun 01, 2010

8:42 AM

Immunomedics to Report Progress on Cancer Imaging and Therapy in 9 Presentations at the Society of Nuclear Medicine's 57th Annual Meeting - Globe Newswire

Tue, May 25, 2010

11:02 AM

Immunomedics Receives Second Milestone Payment From Nycomed - Globe Newswire

Thu, May 13, 2010

8:31 AM

Results From Randomized Study of Epratuzumab in Patients With Lupus to be Presented at European Rheumatology Congress - Globe Newswire

Mon, May 10, 2010

8:35 AM

Immunomedics Announces Third Quarter Fiscal 2010 Results and Clinical Program Developments - Globe Newswire

6:51 AM

BioPharma Stock Alert for Immunomedics Inc. Issued by MicroStockProfit - Globe Newswire

Wed, Apr 21, 2010

8:34 AM

Immunomedics Develops Potent Immunotoxins Against Solid and Liquid Tumors - Globe Newswire

More News for IMMU >>

Tags for Immunomedics Inc.

Research stocks or mutual funds related to Immunomedics Inc. by keywords or tags. Find companies that have a similar focus to IMMU. The keywords below have been associated to IMMU by either user submission or electronic means.

corporate governance quotient investor relations company corporate financial clinical development clinical cost corporate governance training Commercial Physical And Biological Research (8731) disney annual report biotech europe hong kong stock quote board of director clinical diagnostics financial information financial annual report europe pharmaceuticals annual report annual reports disney corporate governance financial report corporate governance issues clinical research medical device distributor business development europe investor relations data define corporate governance board of directors role good corporate governance nyse stock quote clinical trials industry online investor relations corporate governance disclosure board of directors governance board governance role of the board of directors Drugs annual report of company europe profile corporate annual report good governance pharma clinical trials antibody manufacturing 3m annual report financial stock report what is it governance corporate governance and compliance compliance duties of directors financial investor clinical trials europe pharmaceutical distributor

Bookmark With:

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.